Working together to develop innovative treatments
Partnerships are a critical part of the AGTC’s growth strategy. The company is actively exploring alliances that complement our expertise in AAV gene therapy product development with important scientific, clinical and business capabilities. These alliances may incorporate our AAV technology platform, product candidates and/or gene therapy product development capabilities.
To inquire regarding partnership opportunities with AGTC, please contact:
One Kendall Square, 1400W, Suite B14305
Cambridge, MA 02139
O: 617.843.5728 ext 7206
AGTC has a long-standing collaboration with the Alpha-1 Foundation, a patient-focused organization that is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency.
AGTC is sponsoring a clinical study evaluating the natural history of patients with achromatopsia at several leading centers of inherited retinal diseases, including the Bascom Palmer Eye Institute. The principal investigator at the BPEI is Dr. Byron Lam.
In July 2015, AGTC and Biogen entered into a broad collaboration and license agreement to develop a portfolio of AGTC’s therapeutic programs. The lead programs in the collaboration are X-linked Retinoschisis (XLRS) and X-Linked Retinitis Pigmentosa (XLRP). Biogen made an upfront payment in the amount of $124 million to AGTC, which includes a $30 million equity investment. Biogen was also granted an option to license discovery programs for three jointly developed additional indications at the time of clinical candidate selection. Under the collaboration, Biogen will pay for substantially all of the related program development costs and AGTC is eligible to receive upfront and milestone payments exceeding $1 billion along with royalties in the mid-single digits to low teen percentages of annual net sales. Biogen obtained worldwide commercialization rights for the XLRS and XLRP programs with AGTC having an option to share development costs and profits after the initial clinical trial data are available. AGTC also has an option to co-promote the second of these products to be approved in the United States. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. Biogen will also receive an exclusive license to use AGTC’s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC’s discretion, in exchange for payment of milestones and royalties.
AGTC is sponsoring a clinical study evaluating the natural history of patients with achromatopsia at several leading centers of inherited retinal diseases, including the Pangere Center for Inherited Retinal Diseases at the Chicago Lighthouse for people who are blind or visually impaired. The principal investigator at the Pangere Center is Dr. Gerald Fishman.
AGTC is sponsoring clinical studies for Alpha-1 Antitrypsin Deficiency is at several leading medical centers, including the Cincinnati Children’s Hospital Medical Center. The principal investigator at CCHMC is Dr. Bruce Trapnell.
AGTC is sponsoring clinical studies for Alpha-1 Antitrypsin Deficiency is at several leading medical centers, including Duke University Medical Center. The principal investigator at DUMC is Dr. Douglas Tyler.
The mission of the Foundation Fighting Blindness, Inc. (FFB) is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa (RP), macular degeneration, Usher syndrome, and the entire spectrum of retinal degenerative diseases. AGTC has partnered with the FFB on several projects to complete proof of concept work and toxicology and biodistribution studies needed to advance treatments for various retinal degenerative diseases to the clinic.
AGTC is sponsoring a clinical study evaluating the natural history of patients with achromatopsia at several leading centers of inherited retinal diseases, including the Medical College of Wisconsin. The principal investigator at MCW is Dr. Joseph Carroll.
AGTC works with Dr. Andras Komaromy at Michigan State University's College of Veterinary Medicine developing and testing dog models of ophthalmology disease.
AGTC is sponsoring clinical studies for Alpha-1 Antitrypsin Deficiency is at several leading medical centers, including National Jewish Health. The principal investigator is Dr. Robert Sandhaus.
AGTC is working with the Casey Eye Institute to complete Phase 2 studies for a potential treatment for LCA and large animal studies for XLRS. As part of Oregon Health & Science University, the Casey Eye Institute is an academic regional eye center. It is named after James and George Casey, founders of United Parcel Service. The Casey Eye Institute is also one of only seven regional eye research centers in the nation sponsored by Research to Prevent Blindness, the world's leading voluntary organization in support of eye research. The Casey Eye Institute has operated the Elks Children’s Eye Clinic since 1949, thanks to the generous support of the Oregon State Elks Association.
AGTC is sponsoring a clinical study evaluating the natural history of patients with achromatopsia at several leading centers of inherited retinal diseases, including the Retina Foundation of the Southwest in Dallas, TX. The principal investigator at RFSW is Dr. David Birch.
AGTC has extensive ties to the University of Florida and has multiple Sponsored Research Agreements with the University, including with the Department of Ophthalmology, the Powell Gene Therapy Center, and the Alpha-1 Research Foundation at UF. These contracts cover basic research for many new product candidates, support of clinical trials for Alpha-1, and projects that will enhance the basic AAV technology platform. UF is also one of the centers conducting an AGTC-sponsored clinical study evaluating the natural history of patients with achromatopsia. The principal investigator at UF is Dr. Christine Kay.
Two of AGTC’s product candidates, treatments for Alpha-1 Antitrypsin Deficiency and Leber Congenital Amaurosis, are in Phase 2 testing at The University of Massachusetts Medical School. It is one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. Additionally, Dr. Terence Flotte, dean of the School of Medicine, has been a Principal Investigator on several clinical trials of AGTC's Alpha-1 product and continues to provide important advice on development of this product. The Medical School attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care.
AGTC works closely with researchers at the University of Pennsylvania’s Immunology Core under the direction of Dr. James Wilson and Dr. Roberto Calcedo to understand the immunology of AAV vectors used in both animal and human studies. AGTC also works with Dr. Gustavo Aguirre at the University’s Veterinary School developing and testing dog models of ophthalmology disease.